STAAR Surgical (STAA) delivered a quarter in which the demand story improved and the profit story weakened. The company reported third-quarter earnings of $0.11 per share, well short of the $0.19 consensus and the $0.25 Earnings Whisper number, a 56.0% miss. Earnings fell 63.3% year over year. Revenue of $83.41 million beat consensus by 2.3% but fell 12.0% from a year ago. The $0.11 is GAAP net income, while consensus was on a non-GAAP basis, which complicates a clean comparison. Even so, the direction is clear: the top line is outrunning expectations, and the bottom line is not keeping up. That is the central tension.

The year-over-year revenue decline overstates the weakness. The prior-year quarter included $25.9 million of deferred China sales from a 2024 shipment, recognized at a 100% gross margin. Excluding that, net sales rose 21%, China grew 31% to $39.3 million, and the year-ago quarter would have shown a net loss of $6.3 million. Sequential trends are a fairer test of this quarter's earnings quality, and they are less flattering:

• Gross margin fell to 70.9% from 74.5% in the second quarter and 73.6% in the first.
• Adjusted EBITDA slid for a second straight quarter, from $24.4 million to $20.0 million to $14.4 million.
• Net income dropped to $5.6 million from $8.1 million.

Management blamed temporary factors: high unit costs from low second-quarter production during the ERP rollout, freight, tariffs on U.S.-made lenses bound for China, and larger provisions for expiring inventory. A lower tax provision helped GAAP results.

Beneath the margin pressure, demand accelerated. Distributor in-market unit volume in China grew 12.4% through nine months, up from mid-single digits in 2025. Distributor inventory ended below the six-month target, so shipments should more closely track sell-through. Sales outside China grew 13%, up from 6% in each of the first two quarters. EMEA rose 31%, or 51% excluding the Middle East. The Americas grew 14%, and U.S. sales topped $6 million for a third straight quarter even as laser vision correction procedures fell 5.8%. The caveat is that STAAR could not meet lens demand. Every dollar of China growth came from higher average selling prices, driven by the EVO+ and toric mix, not from more units. Supply was expected to catch up by the end of the third quarter but did not, and manufacturing yields remain below historical levels. Rising prices with flat volume is a credible mix story. It also leaves a volume question that bears can fairly press.

The forward picture leans on execution rather than formal targets. STAAR still provides no guidance and has not set timing for 2027 guidance. The earlier hope of exiting the year near a 75% gross margin has become a more modest promise:

• Fourth-quarter gross margin above third-quarter levels.
• Unit costs elevated through year-end as second-quarter inventory sells through.
• Further cost improvement in 2027, now that both plants run at full capacity and all China-bound lenses are made in Switzerland.

China revenue is expected to decline sequentially in the fourth quarter on seasonality while still growing year over year. Management reaffirmed the $225 million operating-expense target.

The catalysts are real:

• First-in-human trials for two presbyopia lenses are expected to begin enrollment within months, pending remaining regulatory authorizations.
• Label expansions extend the U.S. eligibility age to 60 and lower Brazil's minimum prescription to -0.5 diopters.
• Leadership additions include the return of former CEO David Bailey as Chief Commercial Officer.

The balance sheet supports the strategy. Quarterly free cash flow reached $26.4 million, helped by a $12.1 million reduction in receivables. Cash and investments rose to $206.4 million with no debt, and the board authorized a $50 million buyback.

Investor sentiment improved notably heading into the report, rising from 0.15 to 0.40, so expectations were building. The $0.25 Whisper number, above consensus, reflects that. Before the report, shares sat at $25.17, up 4.5% since the opening after the August report and 6.5% above the 200-day moving average. They were about 4% below the inter-earnings high of $26.25 and well above the September 24 low of $19.05. The stock entered earnings near the upper end of its range, with momentum and AVWAP readings positive but the price trend negative. Shares ran up after the last report and then fell sharply, so investors have already seen how quickly optimism can reverse.

The bottom line is that STAAR's demand story strengthened this quarter: unit growth in China accelerated, sales outside China doubled their growth rate, and the pipeline moved closer to the clinic. The earnings miss, three straight quarters of margin and EBITDA erosion, and unresolved supply constraints mean the profit recovery has been pushed out. Fourth-quarter gross margin and evidence that capacity can finally deliver unit growth in China are the tests that will determine whether rising sentiment was justified.